Use of a small-scale filler can result in increased filling efficiency.
Filling of syringes and vials with high-viscosity monoclonal antibodies (mAbs) or small-molecule liquid formulations is a difficult task and may present several challenges. Considerable development work may be required to develop a filling process that provides a clean fill using a small-scale or at-scale filling machine. However, performing the development work using an at-scale filling machine is neither an efficient nor cost-effective long-term option due to hectic manufacturing schedules and associated resource needs. A small-scale filling line can be used to define optimal filling process parameters, support technology transfer, and develop mitigation strategies for ongoing or potential issues with minimal disruption of normal manufacturing operation. Streamlined ways of working without requiring manufacturing-scale line time is expected to result in increased efficiency and improved portfolio progression timelines. Key learnings, case studies, and recommendations for this small-scale filler are discussed.
Click here for a PDF of this article.Submitted: Aug. 19, 2022
Accepted: April 7, 2023
Kevin Hutter*, Kevin.x.hutter@gsk.com, is investigator; Kashappa Goud Desai is scientific leader; Igor Rusanov is principal investigator; and Aarti Gidh is director; all at Process Engineering and Analytics, Drug Product Development, GSK.
*To whom all correspondence should be addressed.
BioPharm International
Volume 36, No. 7
July 2023
Pages: 28–33
When referring to this article, please cite it as Hutter, K.; Desai, K. G.; Rusanov, I.; Gidh, A. Small-Scale Syringe and Vial-Filling Capability for Development of Robust Filling Processes, Smooth Tech Transfers, and to Resolve Manufacturing Issues: Summary of Key Learnings. BioPharm International 2023, 36 (7), 28–33.